Health and Human Services Secretary Robert F. Kennedy Jr., serving in the Trump administration, has called for a comprehensive FDA review of the abortion pill mifepristone.
His request comes in response to a recent Ethics and Public Policy Center study showing that nearly 11% of women experience serious complications, such as infection, hemorrhaging, or sepsis, after using the drug, a rate far higher than the FDA’s current estimate of less than 0.5%.
This call also follows pressure from more than 100 pro-life leaders nationwide. Kennedy emphasized the urgent need to update safety warnings as lawmakers work to reinstate stricter regulations on the medication.
Read more here.